Celldex Announces Public Offering of Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CLDX?
Source: Newsfilter
- Offering Size: Celldex Therapeutics announced a public offering of 10,345,000 shares at $29.00 per share, expected to raise approximately $300 million, reflecting strong market demand and investor confidence in the company.
- Underwriter Selection: The offering is managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor, indicating the company's focus on reputable underwriters to ensure successful capital raising and market impact.
- Use of Proceeds: Celldex intends to utilize the net proceeds from this offering to fund commercial readiness and launch of barzolvolimab, along with ongoing clinical and preclinical development, thereby enhancing its product pipeline and competitive positioning.
- Compliance and Transparency: The offering is conducted under SEC's S-3 registration statement, ensuring compliance and transparency, which further builds investor trust in the company's governance and financial health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLDX
Wall Street analysts forecast CLDX stock price to rise
10 Analyst Rating
9 Buy
0 Hold
1 Sell
Strong Buy
Current: 31.720
Low
24.00
Averages
55.00
High
90.00
Current: 31.720
Low
24.00
Averages
55.00
High
90.00
About CLDX
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Celldex Announces Public Offering of Shares
- Offering Size: Celldex Therapeutics announced a public offering of 10,345,000 shares at $29.00 per share, expected to raise approximately $300 million, reflecting strong market demand and investor confidence in the company.
- Underwriter Selection: The offering is managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor, indicating the company's focus on reputable underwriters to ensure successful capital raising and market impact.
- Use of Proceeds: Celldex intends to utilize the net proceeds from this offering to fund commercial readiness and launch of barzolvolimab, along with ongoing clinical and preclinical development, thereby enhancing its product pipeline and competitive positioning.
- Compliance and Transparency: The offering is conducted under SEC's S-3 registration statement, ensuring compliance and transparency, which further builds investor trust in the company's governance and financial health.
See More
Celldex Therapeutics Prices Public Offering of 10.3 Million Shares
- Offering Size: Celldex Therapeutics announced a public offering of 10,345,000 shares at a price of $29.00 per share, expecting to raise approximately $300 million in gross proceeds, which will significantly enhance the company's financial strength to support future R&D and commercialization activities.
- Underwriter Selection: The offering is managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor, reflecting strong market confidence in Celldex while providing robust capital market support for the company.
- Planned Use of Proceeds: Celldex intends to use the net proceeds from this offering to fund commercial readiness and launch of barzolvolimab, along with ongoing clinical and preclinical development, indicating the company's proactive strategy in drug development and market entry.
- Compliance and Transparency: The offering is made under a previously filed S-3 registration statement, ensuring compliance and transparency, which further enhances investor trust in Celldex and lays a solid foundation for future capital operations.
See More
Celldex Initiates Underwritten Public Offering to Support New Drug Launch
- Public Offering Launch: Celldex Therapeutics has announced the commencement of an underwritten public offering to sell shares of its common stock, with an expected 30-day option for underwriters to purchase an additional 15% of the shares to enhance financing flexibility.
- Clear Use of Proceeds: The net proceeds from this offering will be combined with existing cash and marketable securities, primarily aimed at funding the commercial readiness and launch of barzolvolimab for the treatment of chronic spontaneous urticaria, pending approval.
- Ongoing R&D Advancement: Celldex plans to utilize the offering proceeds to continue the clinical and preclinical development of its product candidates, particularly focusing on the current and future development of barzolvolimab, while also expanding its bispecific antibody platform and clinical candidates.
- Strategic Corporate Positioning: This financing not only supports new drug development but also provides funding for the development of other clinical pipeline products, demonstrating Celldex's proactive positioning for future market opportunities.
See More
Celldex's Barzolvolimab Enhances Quality of Life in Chronic Urticaria Patients
- Clinical Trial Results: Celldex presented positive data on Barzolvolimab at the 2026 American Academy of Dermatology Annual Meeting, showing that up to 51% of chronic spontaneous urticaria patients achieved complete symptom-free response at 12 weeks, increasing to 71% at 52 weeks, indicating significant efficacy in improving patient quality of life.
- Quality of Life Improvement: Among patients treated for 52 weeks, 94% had a DLQI score of 0/1 at week 52, indicating no impact of the disease on their quality of life, with 76% reporting significantly reduced impact at week 76, demonstrating the drug's long-term effectiveness.
- Broad Domain Improvement: The study revealed that Barzolvolimab significantly improved quality of life across all six DLQI domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment), indicating its potential in chronic urticaria management.
- Future Development Prospects: Celldex is conducting global Phase 3 trials, with topline data expected in Q4 2026, positioning Barzolvolimab as a potential first-line treatment for chronic urticaria and enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Kynam Capital Reduces Stake in Cogent Biosciences by $48 Million
- Share Reduction Details: Kynam Capital disclosed in an SEC filing on February 17, 2026, that it sold 1,720,949 shares of Cogent Biosciences in Q4, with an estimated transaction value of $48.38 million, indicating a cautious approach towards the company's future prospects.
- Ownership Proportion Change: Following this sale, Cogent Biosciences now represents 13.99% of Kynam's reported AUM, yet it remains the fund's largest holding, reflecting ongoing confidence in its core investment despite the reduction.
- Market Performance Analysis: Cogent's stock price surged 360% over the past year, significantly outperforming the S&P 500's 15% gain during the same period, highlighting its strong performance and market recognition in the biotech sector.
- Future Outlook: Cogent's lead product, bezuclastinib, received FDA acceptance, with a target decision date set for December 30, 2026, and with $900.8 million in cash reserves, the company is well-positioned to support future R&D and market expansion efforts.
See More
Celldex's Barzolvolimab Shows Strong Efficacy in Skin Conditions
- Efficacy Consistency: Celldex Therapeutics' Barzolvolimab demonstrates that retreatment yields the same profound efficacy in patients with Cold Urticaria and Symptomatic Dermographism, indicating its potential to transform treatment strategies for chronic skin conditions.
- Clinical Trial Results: In a Phase 2 open-label extension study, patients who experienced symptom recurrence regained high levels of disease control upon retreatment, with complete response rates consistent with first-time treatment, underscoring the drug's sustained effectiveness.
- Good Safety Profile: Barzolvolimab was well tolerated, with a safety profile in line with earlier studies, supporting its application in real-world treatment scenarios, particularly for patients requiring intermittent therapy.
- Global Research Initiative: Celldex is currently conducting a global Phase 3 program, EMBARQ, to further evaluate Barzolvolimab's efficacy in Cold Urticaria and Symptomatic Dermographism, signaling potential market expansion in the future.
See More
Celldex Announces Public Offering of Shares
- Offering Size: Celldex Therapeutics announced a public offering of 10,345,000 shares at $29.00 per share, expected to raise approximately $300 million, reflecting strong market demand and investor confidence in the company.
- Underwriter Selection: The offering is managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor, indicating the company's focus on reputable underwriters to ensure successful capital raising and market impact.
- Use of Proceeds: Celldex intends to utilize the net proceeds from this offering to fund commercial readiness and launch of barzolvolimab, along with ongoing clinical and preclinical development, thereby enhancing its product pipeline and competitive positioning.
- Compliance and Transparency: The offering is conducted under SEC's S-3 registration statement, ensuring compliance and transparency, which further builds investor trust in the company's governance and financial health.
See More
Celldex Therapeutics Prices Public Offering of 10.3 Million Shares
- Offering Size: Celldex Therapeutics announced a public offering of 10,345,000 shares at a price of $29.00 per share, expecting to raise approximately $300 million in gross proceeds, which will significantly enhance the company's financial strength to support future R&D and commercialization activities.
- Underwriter Selection: The offering is managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor, reflecting strong market confidence in Celldex while providing robust capital market support for the company.
- Planned Use of Proceeds: Celldex intends to use the net proceeds from this offering to fund commercial readiness and launch of barzolvolimab, along with ongoing clinical and preclinical development, indicating the company's proactive strategy in drug development and market entry.
- Compliance and Transparency: The offering is made under a previously filed S-3 registration statement, ensuring compliance and transparency, which further enhances investor trust in Celldex and lays a solid foundation for future capital operations.
See More
Celldex Initiates Underwritten Public Offering to Support New Drug Launch
- Public Offering Launch: Celldex Therapeutics has announced the commencement of an underwritten public offering to sell shares of its common stock, with an expected 30-day option for underwriters to purchase an additional 15% of the shares to enhance financing flexibility.
- Clear Use of Proceeds: The net proceeds from this offering will be combined with existing cash and marketable securities, primarily aimed at funding the commercial readiness and launch of barzolvolimab for the treatment of chronic spontaneous urticaria, pending approval.
- Ongoing R&D Advancement: Celldex plans to utilize the offering proceeds to continue the clinical and preclinical development of its product candidates, particularly focusing on the current and future development of barzolvolimab, while also expanding its bispecific antibody platform and clinical candidates.
- Strategic Corporate Positioning: This financing not only supports new drug development but also provides funding for the development of other clinical pipeline products, demonstrating Celldex's proactive positioning for future market opportunities.
See More
Celldex's Barzolvolimab Enhances Quality of Life in Chronic Urticaria Patients
- Clinical Trial Results: Celldex presented positive data on Barzolvolimab at the 2026 American Academy of Dermatology Annual Meeting, showing that up to 51% of chronic spontaneous urticaria patients achieved complete symptom-free response at 12 weeks, increasing to 71% at 52 weeks, indicating significant efficacy in improving patient quality of life.
- Quality of Life Improvement: Among patients treated for 52 weeks, 94% had a DLQI score of 0/1 at week 52, indicating no impact of the disease on their quality of life, with 76% reporting significantly reduced impact at week 76, demonstrating the drug's long-term effectiveness.
- Broad Domain Improvement: The study revealed that Barzolvolimab significantly improved quality of life across all six DLQI domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment), indicating its potential in chronic urticaria management.
- Future Development Prospects: Celldex is conducting global Phase 3 trials, with topline data expected in Q4 2026, positioning Barzolvolimab as a potential first-line treatment for chronic urticaria and enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Kynam Capital Reduces Stake in Cogent Biosciences by $48 Million
- Share Reduction Details: Kynam Capital disclosed in an SEC filing on February 17, 2026, that it sold 1,720,949 shares of Cogent Biosciences in Q4, with an estimated transaction value of $48.38 million, indicating a cautious approach towards the company's future prospects.
- Ownership Proportion Change: Following this sale, Cogent Biosciences now represents 13.99% of Kynam's reported AUM, yet it remains the fund's largest holding, reflecting ongoing confidence in its core investment despite the reduction.
- Market Performance Analysis: Cogent's stock price surged 360% over the past year, significantly outperforming the S&P 500's 15% gain during the same period, highlighting its strong performance and market recognition in the biotech sector.
- Future Outlook: Cogent's lead product, bezuclastinib, received FDA acceptance, with a target decision date set for December 30, 2026, and with $900.8 million in cash reserves, the company is well-positioned to support future R&D and market expansion efforts.
See More
Celldex's Barzolvolimab Shows Strong Efficacy in Skin Conditions
- Efficacy Consistency: Celldex Therapeutics' Barzolvolimab demonstrates that retreatment yields the same profound efficacy in patients with Cold Urticaria and Symptomatic Dermographism, indicating its potential to transform treatment strategies for chronic skin conditions.
- Clinical Trial Results: In a Phase 2 open-label extension study, patients who experienced symptom recurrence regained high levels of disease control upon retreatment, with complete response rates consistent with first-time treatment, underscoring the drug's sustained effectiveness.
- Good Safety Profile: Barzolvolimab was well tolerated, with a safety profile in line with earlier studies, supporting its application in real-world treatment scenarios, particularly for patients requiring intermittent therapy.
- Global Research Initiative: Celldex is currently conducting a global Phase 3 program, EMBARQ, to further evaluate Barzolvolimab's efficacy in Cold Urticaria and Symptomatic Dermographism, signaling potential market expansion in the future.
See More
